“We expected cells without working autophagy to struggle,” said Johan Rockberg, professor of directed evolution at KTH Royal Institute of Technology, regarding a new method to boost protein yields.
Researchers have discovered that disabling a cell’s internal recycling system significantly increases the production of membrane proteins, a breakthrough that could lower drug development costs.
The study, published in the journal Cell Systems, addresses a long-standing challenge in pharmaceutical research. While membrane proteins serve as the targets for approximately 60 percent of all approved medicines, they are notoriously difficult to manufacture in the quantities required for large-scale development.
The research team, a collaboration between KTH and AstraZeneca, focused on the gene ULK1. This gene initiates autophagy, the process by which cells break down and recycle their own organelles and proteins. By knocking out this gene, the researchers effectively disabled the cell’s “clean-up crew,” a move that defied conventional expectations of cellular health.
“Instead, they produced more, and they did best with exactly the proteins that are usually hardest to obtain,” Rockberg said. The experiment successfully increased the yield of three specific target proteins—GIPR, GPR75, and P2X3—by 30, 80, and 100 percent, respectively.
To determine why the cells thrived despite the genetic modification, doctoral student Alice Karlsson examined the internal activity of the modified cell lines. She discovered that the knockout led to a clear downregulation of autophagy and its downstream processes, which unexpectedly resulted in higher yields of the model proteins.
“The most rewarding part was seeing the effect of knocking out ULK1 and that it led to clear signs in the transcriptome with downregulation of autophagy and downstream processes,” Karlsson said. She said that the increase in protein production was the “biggest surprise” of the investigation.
| Target Protein | Production Increase |
|---|---|
| GIPR | 30% |
| GPR75 | 80% |
| P2X3 | 100% |
Beyond the immediate goal of improving manufacturing efficiency for drug discovery, the findings suggest that autophagy pathways could be a broader target for host cell engineering. The study notes that the observed effects on cellular metabolism and protein turnover may also provide insights into neurodegenerative conditions. These diseases are often characterized by protein aggregation and impaired clearance mechanisms within cells.
Why are membrane proteins difficult to produce?
Membrane proteins are complex structures that require specific cellular environments to fold and function correctly. Their inherent instability makes them hard to manufacture in the high volumes needed for pharmaceutical screening.
Did removing the ULK1 gene harm the cells?
No. While autophagy is generally considered necessary for cell health, the study found that removing the ULK1 gene did not negatively impact the cells, which continued to function and produce protein more efficiently than their unmodified counterparts.
Who funded this research?
The project was supported by the Knut and Alice Wallenberg Foundation, AstraZeneca, and the Swedish innovation agency Vinnova through the initiatives GeneNova, AAVNova, CellNova, and AdBIOPRO.
KTH Royal Institute of Technology, Sweden’s largest technical university, traces its origins to the Laboratorium Mechanicum founded in 1697 by Christopher Polhem. It was formally established as the Teknologiska institutet in 1827 and adopted its current name in 1877. Today, KTH comprises five schools across four campuses in and around Stockholm and was ranked the highest university in the Nordic countries by the 2025 QS World University Rankings.
The research team, led by authors including Alice Karlsson, Melanie Dannemeyer, and Robert G. Roth, detailed their findings in the November 2026 issue of Cell Systems.
Worth a look